| Dr Jacob Cherian, MD | |
|
5450 Knoll North Dr, Columbia, MD 21045-2300 | |
| (410) 964-5311 | |
| (410) 964-8578 |
| Full Name | Dr Jacob Cherian |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 31 Years |
| Location | 5450 Knoll North Dr, Columbia, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003973637 | NPI | - | NPPES |
| 780011800 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | D50973 (Maryland) | Primary |
| Entity Name | Jacob Cherian Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124204912 PECOS PAC ID: 5799749776 Enrollment ID: O20041118000868 |
News Archive
BioSante Pharmaceuticals, Inc., a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).
A new study led by the University of Oulu in Finland refutes the belief that high hemoglobin levels are always desirable for health.
The Denver Post: In Colorado, Democratic Gov. Bill Ritter is scheduled to sign an executive order Tuesday that "health care advocates say is key to turning the federal government's vague framework for reform into reality." The order "will create a board of health-policy advisers to guide the transition to a new health system — everything from setting up a state insurance exchange to making sure the insurance commissioner has authority to guard against companies rejecting someone for being sick."
Taking a critical step toward the development of a multifunctional nanoscale anticancer agent that can detect cancer, treat it, and then report on the success or failure of that treatment, investigators at the University of Michigan have developed a nanoscale sensor of cell death.
National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jacob Cherian, MD 6286 Tufted Moss, Columbia, MD 21045-4534 Ph: (410) 309-0452 | Dr Jacob Cherian, MD 5450 Knoll North Dr, Columbia, MD 21045-2300 Ph: (410) 964-5311 |
News Archive
BioSante Pharmaceuticals, Inc., a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).
A new study led by the University of Oulu in Finland refutes the belief that high hemoglobin levels are always desirable for health.
The Denver Post: In Colorado, Democratic Gov. Bill Ritter is scheduled to sign an executive order Tuesday that "health care advocates say is key to turning the federal government's vague framework for reform into reality." The order "will create a board of health-policy advisers to guide the transition to a new health system — everything from setting up a state insurance exchange to making sure the insurance commissioner has authority to guard against companies rejecting someone for being sick."
Taking a critical step toward the development of a multifunctional nanoscale anticancer agent that can detect cancer, treat it, and then report on the success or failure of that treatment, investigators at the University of Michigan have developed a nanoscale sensor of cell death.
National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.
› Verified 5 days ago
Dr. Jon Kent Minford, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 10710 Charter Dr, Suite G020, Columbia, MD 21044 Phone: 410-964-2212 Fax: 410-964-0380 | |
Dr. Tejaswi Rajasekhara Sastry, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10710 Charter Dr, Suite G020, Columbia, MD 21044 Phone: 410-964-2212 Fax: 410-964-0380 | |
Michael Howard Kelemen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5450 Knoll North Dr, Suite 200b, Columbia, MD 21045 Phone: 410-964-5303 | |
Dr. Tin O Maung, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5999 Harpers Farm Rd, Suite W250, Columbia, MD 21044 Phone: 410-772-8822 Fax: 410-772-9274 | |
Dr. Jeffery Wayne Van Den Broek, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10710 Charter Dr, Suite 110, Columbia, MD 21044 Phone: 410-992-9797 Fax: 410-730-0942 | |
Angela M. Kopack, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 11055 Little Patuxent Pkwy, Suite 209, Columbia, MD 21044 Phone: 410-884-1311 Fax: 410-884-6033 |